Sentiment-Signal
24,4
Bearisch
Composite Score (0–100)
Insider (25%)
29.9
1 Insider, 501K $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 25.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 02.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 29.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 08.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 04.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | r not involving a public offering. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
Stammdaten
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Unternehmen & Branche
| Name | Immunome Inc. |
|---|---|
| Ticker | IMNM |
| CIK | 0001472012 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,07 Mrd. USD |
| Beta | 2,14 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 6,941,000 | -212,394,000 | -2.43 | 683,188,000 | 634,343,000 |
| 2025-09-30 | 10-Q | 0 | -57,457,000 | -0.65 | 299,377,000 | 263,919,000 |
| 2025-06-30 | 10-Q | 4,015,000 | -43,397,000 | -0.50 | 296,290,000 | 269,270,000 |
| 2025-03-31 | 10-Q | 2,926,000 | -41,640,000 | -0.52 | 342,693,000 | 307,126,000 |
| 2024-12-31 | 10-K | 9,041,000 | -292,963,000 | -5.00 | 240,241,000 | 181,165,000 |
| 2024-09-30 | 10-Q | 2,910,000 | -47,100,000 | -0.78 | 256,898,000 | 214,906,000 |
| 2024-06-30 | 10-Q | 2,364,000 | -36,122,000 | -0.60 | 296,215,000 | 253,838,000 |
| 2024-03-31 | 10-Q | 1,029,000 | -129,492,000 | -2.51 | 319,754,000 | 285,572,000 |
| 2023-12-31 | 10-K | 14,018,000 | -106,806,000 | -5.38 | 148,540,000 | 119,882,000 |
| 2023-09-30 | 10-Q | 3,565,000 | -4,345,000 | -0.36 | 93,161,000 | 6,076,000 |
| 2023-06-30 | 10-Q | 4,263,000 | -5,557,000 | -0.46 | 41,435,000 | 9,338,000 |
| 2023-03-31 | 10-Q | 2,364,000 | -4,270,000 | -0.35 | 48,114,000 | 13,862,000 |
| 2022-12-31 | 10-K | -36,896,000 | -3.09 | 24,046,000 | 16,653,000 | |
| 2022-09-30 | 10-Q | -8,533,000 | -0.75 | 30,546,000 | 23,084,000 | |
| 2022-06-30 | 10-Q | -8,924,000 | -0.74 | 39,019,000 | 30,277,000 | |
| 2022-03-31 | 10-Q | -11,653,000 | -0.96 | 47,728,000 | 37,874,000 | |
| 2021-12-31 | 10-K | -24,711,000 | -2.14 | 57,925,000 | 48,185,000 | |
| 2021-09-30 | 10-Q | -7,720,000 | -0.65 | 62,558,000 | 54,793,000 | |
| 2021-06-30 | 10-Q | -5,241,000 | -0.46 | 64,141,000 | 60,617,000 | |
| 2021-03-31 | 10-Q | -3,898,000 | -0.37 | 42,593,000 | 37,883,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Higgins Jack | Officer, Chief Scientific Officer | Open Market Sale | -9,438 | 21.64 | -204,238.32 | -23,0% | |
| 2026-04-02 | Rosett Max | Officer, Chief Financial Officer | Open Market Sale | -63,656 | 21.91 | -1,394,702.96 | -156,8% | |
| 2026-04-02 | Rosett Max | Officer, Chief Financial Officer | Open Market Sale | -1,344 | 22.48 | -30,213.12 | -3,4% | |
| 2026-03-27 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 25,450 | 19.67 | 500,601.50 | +56,3% | |
| 2026-03-23 | WAGENHEIM PHILIP | Director | Open Market Sale | -28,200 | 20.65 | -582,330.00 | -65,5% | |
| 2026-03-20 | WAGENHEIM PHILIP | Director | Open Market Sale | -36,800 | 20.47 | -753,296.00 | -84,7% | |
| 2026-03-11 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 21.55 | 21,550.00 | +2,4% | |
| 2026-03-10 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 1,000 | 22.12 | 22,120.00 | +2,5% | |
| 2025-12-30 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 4,729 | 21.15 | 100,018.35 | +11,2% | |
| 2025-12-22 | Barchas Isaac | Director | Open Market Sale | -371,949 | 21.72 | -8,078,732.28 | -908,4% | |
| 2025-12-22 | Barchas Isaac | Director | Open Market Sale | -11,251 | 22.34 | -251,347.34 | -28,3% | |
| 2025-12-19 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 7,278 | 20.48 | 149,053.44 | +16,8% | |
| 2025-12-19 | Tsai Philip | Officer, Chief Technical Officer | Open Market Purchase | 10,000 | 20.49 | 204,900.00 | +23,0% | |
| 2025-12-18 | SIEGALL CLAY B | Director, Officer, President and CEO | Open Market Purchase | 46,511 | 21.50 | 999,986.50 | +112,4% | |
| 2025-06-03 | BIENAIME JEAN JACQUES | Director | Open Market Purchase | 5,000 | 9.38 | 46,900.00 | +5,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.